Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
about
Focus on adoptive T cell transfer trials in melanomaCentral memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cellsAdoptive immunotherapy for cancer: building on successDurable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapyGene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenAdoptive cell transfer: a clinical path to effective cancer immunotherapyA balanced review of the status T cell-based therapy against cancerAdoptive T cell therapy: Addressing challenges in cancer immunotherapyProgress and controversies in developing cancer vaccines.Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor ImmunityInvestigative and clinical applications of synthetic immune synapsesSorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookTumor infiltrating lymphocytes in ovarian cancerGenetically modified T cells in cancer therapy: opportunities and challengesLineage relationship of effector and memory T cellsProliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaquesTechnical Considerations for the Generation of Adoptively Transferred T Cells in Cancer ImmunotherapyT-cell receptor gene therapy--ready to go viral?Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factorsHow (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transferBET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy modelsSafety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasUnbiased analysis of TCRα/β chains at the single-cell level in human CD8+ T-cell subsetsAdoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.Phase I clinical trial of fibronectin CH296-stimulated T cell therapy in patients with advanced cancer.Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cellsTherapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systemsThe future is now: chimeric antigen receptors as new targeted therapies for childhood cancerTumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposureCAR-modified T-cell therapy for cancer: an updated review.Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)
P2860
Q21328679-B2A58C69-8B41-4DA7-AB3B-A0B1754BF4D1Q24530100-DE5B84B2-B011-4BFD-8279-B9B87B6979A5Q24546258-C905A38C-263E-48BE-A757-1D9F6E3C7F4EQ24596055-62E09C74-701F-4B8A-8AA9-0825380D54BBQ24623215-8C638BAD-FB2D-49E1-8453-842E2F714923Q24644774-7A74735F-F8AD-471A-B100-4F976391CBEDQ24800636-E0D91720-90AC-47DA-9E39-2067F06E1A84Q24805804-7865A9B7-5FF1-4309-A6BA-6A5775003481Q24810256-8E20A99E-FE6D-4AD1-A519-FBD65DDB454CQ26782201-7EB42478-C2CB-4200-B804-CA40DBBC216EQ26825315-C20009BC-EB1A-474C-BD67-85270460E9C1Q27002575-B3F94D7C-51C3-4959-A6BC-1916D0DF6192Q27004178-AE3FAA7B-11C0-4420-BA3A-13D0E86FFF28Q27021878-66312D8D-822E-40B7-9567-24A7066A220CQ27026627-CB1FB228-76F6-4174-9856-95BBA1960F81Q27026665-A6EFD80C-236C-46D4-B5C0-6ADEF2C25C10Q27314843-345D3D0C-E1EE-4C79-B6B2-E3740D6397E1Q28073563-274D6FDB-FFDA-4D06-878B-0D3CA6F3A585Q28081611-EC200C23-E612-48AE-8C4F-7B1A48E27E95Q28652288-027C602F-6558-4E2C-A7C1-2926763EB852Q28727481-F1E7DAB3-030A-461A-AF8C-443B6F459825Q28828457-2EAA2624-60B1-49D4-A047-3B5EAFA7258EQ29622949-4EDAE984-AB69-4C92-A2C2-34C0AD3F0C0EQ31072111-7A1BA6A4-BDD5-42D2-821C-E52D724A59DEQ33261122-F2088D2D-BB3F-4DFF-A46A-53EB5E7AF0F7Q33413155-C18EEE6D-22AE-4A9A-BD1D-AAACCF113FB4Q33440852-7C47ED12-D261-4BCE-9ECB-F7D0F00AB72EQ33526549-8EC99266-ABD6-491A-8298-79BAB272741DQ33530527-B6A15C39-E0FC-4BB4-B550-2B41A1B60F91Q33588711-7FB48C1D-5F3F-4D3B-B086-BC96AEAA61B4Q33603041-E4A8285E-CC95-44AF-8FDF-F0A6E25A5CADQ33761188-FCCC803C-4275-42BE-976D-99115DF97D31Q33831940-46E5AEEE-62F1-47FF-98CE-0884D8AC164FQ33849560-9B70E4AD-7EAE-4BAF-A850-1FB233C6C80EQ33928557-57B4779C-C7C7-4004-9637-B57C6EAF3F7DQ33993529-29E2D6D8-5CC1-44CB-B6C5-41E9F61257F5Q33993999-D97ADD4D-D39E-4FFB-9F0E-355E76FE53B0Q34044213-F1BFA57C-AF33-4299-8E2A-BFC755A2C95FQ34055865-E336D5CF-55ED-4FB5-81BE-10A8D0E1D134Q34073529-7308284D-76BC-4C9E-989F-696CE6978F68
P2860
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Cutting edge: persistence of t ...... eceiving cell transfer therapy
@ast
Cutting edge: persistence of t ...... eceiving cell transfer therapy
@en
type
label
Cutting edge: persistence of t ...... eceiving cell transfer therapy
@ast
Cutting edge: persistence of t ...... eceiving cell transfer therapy
@en
prefLabel
Cutting edge: persistence of t ...... eceiving cell transfer therapy
@ast
Cutting edge: persistence of t ...... eceiving cell transfer therapy
@en
P2093
P2860
P1476
Cutting edge: persistence of t ...... eceiving cell transfer therapy
@en
P2093
Daniel J Powell
Jianping Huang
John Wunderlich
Juhua Zhou
Mark E Dudley
Mona El-Gamil
Paul F Robbins
Steven A Rosenberg
P2860
P304
P356
10.4049/JIMMUNOL.173.12.7125
P407
P577
2004-12-01T00:00:00Z